This topic contains a solution. Click here to go to the answer

Author Question: You are a coding manager developing a continuing education session to introduce a newly developed ... (Read 34 times)

CQXA

  • Hero Member
  • *****
  • Posts: 546
You are a coding manager developing a continuing education session to introduce a newly developed policy and set of processes to be followed by all of the coders in a network of providers in your organization. Which area of JOHARI Window would this new process be for the employees receiving the information?
 A) Blind
  B) Hidden
  C) Open
  D) Unknown

Question 2

Which of the following may be added to enhance verbal communication?
 A) Nonverbal cues
  B) Speaking in another language
  C) Speaking louder
  D) Repeating the message



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Perkypinki

  • Sr. Member
  • ****
  • Posts: 339
Answer to Question 1

B

Answer to Question 2

A





 

Did you know?

Anesthesia awareness is a potentially disturbing adverse effect wherein patients who have been paralyzed with muscle relaxants may awaken. They may be aware of their surroundings but unable to communicate or move. Neurologic monitoring equipment that helps to more closely check the patient's anesthesia stages is now available to avoid the occurrence of anesthesia awareness.

Did you know?

Most women experience menopause in their 50s. However, in 1994, an Italian woman gave birth to a baby boy when she was 61 years old.

Did you know?

The lipid bilayer is made of phospholipids. They are arranged in a double layer because one of their ends is attracted to water while the other is repelled by water.

Did you know?

Only one in 10 cancer deaths is caused by the primary tumor. The vast majority of cancer mortality is caused by cells breaking away from the main tumor and metastasizing to other parts of the body, such as the brain, bones, or liver.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library